Treatment and Management of Patients With High-Risk or Advanced HR+/HER2- Breast Cancer
Treatment and Management of Patients With High-Risk or Advanced HR+/HER2- Breast Cancer is organized by Prime Education, LLC.
Release Date: May 4, 2023
Expiration Date:May 3, 2024
Agenda:
• Key Findings From a Quality Improvement Initiative in HR+/HER2- Breast Cancer
• Aligning Clinical Practice With the Latest Clinical Evidence in Oral Therapeutic Approaches for HR+/HER2- Breast Cancer
• Early Recognition, Monitoring, and Management of Adverse Events With Oral HR+/HER2- Breast Cancer Therapies
• Practical Strategies for Improving Adherence and Persistence for Use of Oral Therapies in Breast Cancer
Learning Objectives:
• Align clinical practices with current clinical data and guidelines for identification and appropriate treatment of patients with HR+/HER2- breast cancer who have a high risk of recurrence
• Monitor adverse events associated with oral therapies for HR+/HER2- breast cancer treatment to promptly identify and effectively treat side effects
• Assess current practice patterns and barriers to treatment adherence and persistence in HR+/HER2- breast cancer in community oncology settings
• Evaluate principles of patient-centered care and shared decision-making to management decisions in HR+/HER2- breast cancer
• Apply evidence-based strategies for patient education and counseling regarding treatment efficacy, side effect management, and adherence
• Employ interprofessional strategies for coordinating care for patients with HR+/HER2- breast cancer.